New study: There are large differences in plasma and abilities among the recovered.

Springer Nature's international professional academic journal Nature-Medicine, Nature-Structure and Molecular Biology, published online on the 13th on the new study paper on the outbreak of neo-coronal pneumonia (COVID-19), said that the blood plasma of recovered patients has a wide difference in the medium and ability;a study published in Nature-Medicine by Adam Wheatley of the University of Melbourne, Australia, and colleagues, found that the plasma of 41 adult patients with new coronary pneumonia in Australia contained a large number of antibodies against the new coronavirus "sting", memory B cells (a type of white blood cell that produces antibodies) and circulatory follicle-assisted T cells (cTFH cells, which regulate B-cell immune cells)the study also found that while all patients recovering from neo-coronary pneumonia exhibited multiple characteristics of immuno-identifying the new coronavirus stingy glycoprotein, which promotes the binding of the virus to cells into cells, the plasma of each patient was very differentthey believe that these results suggest that B-cells and cTFH cells with specific surface and functional characteristics may not be useful targets for future vaccine development, and that further large-scale cohort studies are needed to understand the interaction between cTFH cells and neutralized antibodies produced by different vaccinesa paper published in Nature-Structural and Molecular Biology by James Naismith of the Rosalynn Franklin Institute in the United Kingdom and colleagues, human-derived antibodies, like those of most mammals, have heavy and light chains, while camels such as large alpacas have an antibody variant with only a single heavy chain, also known as nanoantibodiesnanoantibodies are small and stable, and are easy to prepare, so they are often used as an alternative to traditional antibodies for diagnostic and imaging, and nanoantibodies are being developed as new coronavirus research tools and potential therapeutic drugsthey reported in their paper two closely related nanoantibodies (H11-H4 and H11-D4), which block the combination of the new coronavirus "sting" and ACE2 in cell cultureboth nano-antibodies show the ability to neutralise the new coronavirus, of which H11-H4 has a particularly high price, and the use of human-derived antibodies can also enhance neutrality and abilityresearchers believe that these nano-antibodies can be used alone or in combination with other antibodies to help patients with severe pneumonia with new coronary pneumonia to achieve passive immunitythey also caution that because camel-derived antibodies are highly conservative to human-derived antibodies, they may only produce a lower immune response in the human body, but they can use well-developed human-derived strategies()